Management of stage T1 tumors of the bladder: International Consensus Panel

Urology

Volumn 66, Issue 6 SUPPL. 1, 2005, Pages 108-125

  Nieder, Alan M ^a   Brausi, Maurizio ^b   Lamm, Donald ^c   O'Donnell, Michael ^d   Tomita, Kyouichi ^e   Woo, Henry ^f   Jewett, Michael A S ^g  

^a STONY BROOK UNIVERSITY   (United States)

^b Nuovo Ospedale S Agostino   (Italy)

^c Bladder Cancer Genitourinary ^*  (United States)

^d UNIVERSITY OF IOWA   (United States)

^e UNIVERSITY OF TOKYO   (Japan)

^f WESTMEAD HOSPITAL   (Australia)

^g UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCG VACCINE; DOXORUBICIN; EPIRUBICIN; ETOGLUCID; MITOMYCIN C; THIOTEPA; VALRUBICIN;

BLADDER BIOPSY; BLADDER TUMOR; CANCER STAGING; CLINICAL TRIAL; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; CONSERVATIVE TREATMENT; CYSTECTOMY; HUMAN; MEDICAL DECISION MAKING; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE; SEPSIS; TREATMENT FAILURE; TREATMENT PLANNING; TUMOR RECURRENCE; URETHRA; URINARY TRACT; URINARY TRACT DISEASE;

ALGORITHMS; HUMANS; NEOPLASM STAGING; URINARY BLADDER NEOPLASMS;

EID: 30044432091     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2005.08.066     Document Type: Conference Paper

References (108)

1. N. Fujimoto, S. Haradas, M. Terado Multiple biopsies of normal looking urothelium in patients with superficial bladder cancer are they necessary? Int J Urol 10 2003 631 635
2. P. Abrams, A. Grant, S. Khoury Evidence-based medicine overview of the main steps for developing and grading guideline recommendations P. Abrams L. Cardozo S. Khoury Incontinence Volume 1 2005 Health Publications Ltd Plymouth, United Kingdom 10 11
3. A.P. van der Meijden, W. Oostelinck, M. Brausi Significance of bladder biopsies in Ta-T1 bladder tumors a report from EORTC GU Group Eur Urol 35 1999 267 271
4. F. May, V. Treiber, R. Hartung Significance of random bladder biopsies in superficial bladder cancer Eur Urol 44 2003 47 50
5. J.P. Stein Indications for early cystectomy Semin Urol Oncol 18 2000 289 295
6. H.W. Herr The value of a second transurethral resection in evaluating patients with bladder tumors J Urol 162 1999 74 76
7. S.C. Dutta, J.A. Smith Jr, S.B. Shappell Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy J Urol 166 2001 490 493
8. M.A. Zurkirchen, T. Sulser, A. Gaspert Second transurethral resection of superficial transitional cell carcinoma of the bladder a must even for experienced urologists Urol Int 72 2004 99 102
9. M.O. Grimm, C. Steinhoff, X. Simon Effect of routine repeat transurethral resection for superficial bladder cancer a long-term observational study J Urol 170 2003 433 437
10. A. Brauers, R. Buettner, G. Jakse Second resection and prognosis of primary high risk superficial bladder cancer is cystectomy often too early? J Urol 165 2001 808 810
11. L. Schips, H. Augustin, R.E. Zigeuner Is repeated transurethral resection justified in patients with newly diagnosed superficial bladder cancer? Urology 59 2002 220 223
12. M. May, T. Nitzke, C. Helke Significance of the time between muscle invasion and radical cystectomy with regard to the prognosis of transitional cell carcinoma of the urothelium in the bladder Scand J Urol Nephrol 38 2004 231 235
13. L. Cheng, A.L. Weaver, R.M. Neumann Substaging of T1 bladder carcinoma based on the depth of invasion as measured by micrometer a new proposal Cancer 86 1999 1035 1043
14. F. Millan-Rodriguez, G. Chechile-Toniolo, J. Salvador-Bayarri Multivariate analysis of the prognostic factors of primary superficial bladder cancer J Urol 163 2000 73 78
15. E. Solsona, I. Iborra, R. Dumont The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer J Urol 164 2000 685 689
16. H.W. Herr, R.A. Badalament, D.A. Amato Superficial bladder cancer treated with bacillus Calmette-Guérin a multivariate analysis of factors affecting tumor progression J Urol 141 1989 22 29
17. V.B. Lokeshwar, T. Habuchi, H.B. Grossman Bladder tumor markers beyond cytology international consensus panel on bladder tumor markers Urology 66 suppl 6A 2005 35 63
18. A. Sgambato, M. Migaldi, B. Faraglia Cyclin D1 expression in papillary superficial bladder cancer its association with other cell cycle-associated proteins, cell proliferation and clinical outcome Int J Cancer 97 2002 671 678
19. C. Pfister, J.M. Flaman, F. Dunet p53 mutations in bladder tumors inactivate the transactivation of the p21 and Bax genes, and have a predictive value for the clinical outcome after bacillus Calmette-Guérin therapy J Urol 162 1999 69 73
20. T. Lebret, V. Becette, M. Barbagelatta Correlation between p53 over expression and response to bacillus Calmette-Guérin therapy in a high risk select population of patients with T1G3 bladder cancer J Urol 159 1998 788 791
21. F. Saint, M.A. Le Frere Belda, R. Quintela Pretreatment p53 nuclear overexpression as a prognostic marker in superficial bladder cancer treated with bacillus Calmette-Guérin (BCG) Eur Urol 45 2004 475 482
22. L. Lacombe, G. Dalbagni, Z.F. Zhang Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after bacillus Calmette-Guérin therapy correlation to clinical outcome J Clin Oncol 14 1996 2646 2652
23. J. Llopis, A. Alcaraz, M.J. Ribal p53 expression predicts progression and poor survival in T1 bladder tumours Eur Urol 37 2000 644 653
24. G. Steiner, E. Bierhoff, D. Schmidt p53 immunoreactivity in biopsy specimens of T1G3 transitional cell carcinoma of the bladder a helpful parameter in guiding the decision for or against cystectomy? Eur J Cancer 36 2000 610 614
25. S. Jahnson, M.G. Karlsson Predictive value of p53 and pRb immunostaining in locally advanced bladder cancer treated with cystectomy J Urol 160 1998 1291 1296
26. A. Lopez-Beltran, R.J. Luque, J. Alvarez-Kindelan Prognostic factors in stage T1 grade 3 bladder cancer survival the role of G1-S modulators (p53, p21Waf1, p27kip1, cyclin D1, and cyclin D3) and proliferation index (ki67-MIB1) Eur Urol 45 2004 606 612
27. H.W. Herr, M.S. Cookson, S.M. Soloway Upper tract tumors in patients with primary bladder cancer followed for 15 years J Urol 156 1996 1286 1287
28. E.B. Miller, G.R. Eure, P.F. Schellhammer Upper tract transitional cell carcinoma following treatment of superficial bladder cancer with BCG Urology 42 1993 26 30
29. D.M. Schwalb, H.W. Herr, W.R. Fair The management of clinically unconfirmed positive urinary cytology J Urol 150 1993 1751 1756
30. R. Hurle, A. Losa, A. Manzetti Upper urinary tract tumors developing after treatment of superficial bladder cancer 7-year follow-up of 591 consecutive patients Urology 53 1999 1144 1148
31. C.B. Schwartz, H. Bekirov, A. Melman Urothelial tumors of upper tract following treatment of primary bladder transitional cell carcinoma Urology 40 1992 509 511
32. H.W. Herr, W.F. Whitmore Jr Ureteral carcinoma in situ after successful intravesical therapy for superficial bladder tumors incidence, possible pathogenesis and management J Urol 138 1987 292 294
33. R. Hurle, A. Losa, A. Manzetti Intravesical bacille Calmette- Guérin in stage T1 grade 3 bladder cancer therapy a 7-year follow-up Urology 54 1999 258 263
34. A.D. Amar, S. Das Upper urinary tract transitional cell carcinoma in patients with bladder carcinoma and associated vesicoureteral reflux J Urol 133 1985 468 471
35. J.A. De Torres Mateos, J.M. Banus Gassol, J. Palou Redorta Vesicorenal reflux and upper urinary tract transitional cell carcinoma after transurethral resection of recurrent superficial bladder carcinoma J Urol 138 1987 49 51
36. E. Solsona, I. Iborra, J.V. Ricos Upper urinary tract involvement in patients with bladder carcinoma in situ (Tis) its impact on management Urology 49 1997 347 352
37. H.W. Herr Extravesical tumor relapse in patients with superficial bladder tumors J Clin Oncol 16 1998 1099 1102
38. P.F. Schellhammer, L.E. Ladaga, R.P. Moriarty Intravesical bacillus Calmette-Guérin for treatment of superficial transitional cell carcinoma of the prostatic urethra in association with carcinoma of the bladder J Urol 153 1995 53 56
39. W.J. Catalona, M.A. Hudson, D.P. Gillen Risks and benefits of repeated courses of intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer J Urol 137 1987 220 224
40. N. Sakamoto, M. Tsuneyoshi, S. Naito An adequate sampling of the prostate to identify prostatic involvement by urothelial carcinoma in bladder cancer patients J Urol 149 1993 318 321
41. H.W. Herr, S.M. Donat Prostatic tumor relapse in patients with superficial bladder tumors 15-year outcome J Urol 161 1999 1854 1857
42. D.A. Tolley, M.K. Parmar, K.M. Grigor The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer a further report with 7 years of follow up J Urol 155 1996 1233 1238
43. W. Oosterlinck, K.H. Kurth, F. Schroder A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder J Urol 149 1993 749 752
44. C. Bouffioux, K.H. Kurth, A. Bono European Organization for Research and Treatment of Cancer Genitourinary Group Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment J Urol 153 1995 934 941
45. E. Solsona, I. Iborra, J.V. Ricos Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer short and long-term followup J Urol 161 1999 1120 1123
46. S. Krege, G. Giani, R. Meyer A randomized multicenter trial of adjuvant therapy in superficial bladder cancer transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guérin participating clinics J Urol 156 1996 962 966
47. K. Kurth, U. Tunn, R. Ay Adjuvant chemotherapy for superficial transitional cell bladder carcinoma long-term results of a European Organization for Research and Treatment of Cancer randomized trial comparing doxorubicin, ethoglucid and transurethral resection alone J Urol 158 1997 378 384
48. R.J. Sylvester, W. Oosterlinck, A.P. van der Meijden A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer a meta-analysis of published results of randomized clinical trials J Urol 171 2004 2186 2190
49. N.M. Heney, S. Ahmed, M.J. Flanagan Superficial bladder cancer progression and recurrence J Urol 130 1983 1083 1086
50. R.P. Pauwels, R.F. Schapers, A.W. Smeets Grading in superficial bladder cancer (1) morphological criteria Br J Urol 61 1988 129 134
51. P.D. Abel, R.R. Hall, G. Williams Should pT1 transitional cell cancers of the bladder be classified as superficial? Br J Urol 62 1988 235 239
52. L. Henningsohn, H. Wijkstrom, P.W. Dickan Distressful symptoms after radical cystectomy with urinary diversion for urinary bladder cancer a Swedish population-based study Eur Urol 40 2001 151 162
53. G. Dalbagni, E. Genega, M. Hashibe Cystectomy for bladder cancer a contemporary series J Urol 165 2001 1111 1116
54. J.P. Stein, G. Lieskovsky, R. Cote Radical cystectomy in the treatment of invasive bladder cancer long-term results in 1,054 patients J Clin Oncol 19 2001 666 675
55. M.S. Cookson, H.W. Herr, Z.F. Zhang The treated natural history of high risk superficial bladder cancer 15-year outcome J Urol 158 1997 62 67
56. O. Shahin, G.N. Thalmann, C. Rentsch A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guérin for primary stage T1 grade 3 bladder cancer recurrence, progression and survival J Urol 169 2003 96 100
57. D.L. Lamm Efficacy and safety of bacille Calmette-Guérin immunotherapy in superficial bladder cancer Clin Infect Dis 31 suppl 3 2000 S86 S90
58. D.L. Lamm, B.A. Blumenstein, J.D. Crissman Maintenance bacillus Calmette-Guérin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder a randomized Southwest Oncology Group Study J Urol 163 2000 1124 1129
59. A.V. Bono, C. Benvenuti, G. Damiano Results of transurethral resection and intravesical doxorubicin prophylaxis in patients with T1G3 bladder cancer Urology 44 1994 329 334
60. C.L. Amling, J.B. Thrasher, H.A. Frazier Radical cystectomy for stages Ta, Tis and T1 transitional cell carcinoma of the bladder J Urol 151 1994 31 35
61. M.A. Ghoneim, M.M. el-Mekresh, M.A. el-Baz Radical cystectomy for carcinoma of the bladder critical evaluation of the results in 1,026 cases J Urol 158 1997 393 399
62. B. Malavaud T1G3 bladder tumours the case for radical cystectomy Eur Urol 45 2004 406 410
63. F.J. Bianco Jr, D. Justa, D.J. Grignon Management of clinical T1 bladder transitional cell carcinoma by radical cystectomy Urol Oncol 22 2004 290 294
64. H.W. Herr, P.C. Sogani Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J Urol 166 2001 1296 1299
65. A. Morales, D. Eidinger, A.W. Bruce Intracavitary bacillus Calmette-Guérin in the treatment of superficial bladder tumors J Urol 116 1976 180 183
66. S.A. Brosman Experience with bacillus Calmette-Guérin in patients with superficial bladder carcinoma J Urol 128 1982 27 30
67. R.J. Sylvester, A.P. van der Meijden, D.L. Lamm Intravesical bacillus Calmette-Guérin reduces the risk of progression in patients with superficial bladder cancer a meta-analysis of the published results of randomized clinical trials J Urol 168 2002 1964 1970
68. L. Boccon-Gibod, C. Leleu, J.M. Herve Bladder tumors invading the lamina propria (stage T1) influence of endovesical BCG therapy on recurrence and progression Prog Clin Biol Res 310 1989 161 169
69. G.R. Eure, M.R. Cundiff, P.F. Schellhammer Bacillus Calmette- Guérin therapy for high risk stage T1 superficial bladder cancer J Urol 147 1992 376 379
70. M.S. Cookson, M.F. Sorosdy Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guérin therapy J Urol 148 1992 797 801
71. C. Pfister, P. Lande, J.M. Herve T1G3 bladder tumors the respective role of BCG and cystectomy Prog Urol 5 1995 231 237
72. D. Mack, J. Frick Five-year results of a phase II study with low-dose bacille Calmette-Guérin therapy in high-risk superficial bladder cancer Urology 45 1995 958 961
73. V. Pansadoro, P. Emiliozzi, L. Defidio Bacillus Calmette-Guérin in the treatment of stage T1 grade 3 transitional cell carcinoma of the bladder long-term results J Urol 154 1995 2054 2058
74. V. Pansadoro, P. Emiliozzi, F. De Paula Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guérin 18-year experience Urology 59 2002 227 231
75. R. Hurle, A. Losa, A. Ranieri Low dose Pasteur bacillus Calmette-Guérin regimen in stage T1, grade 3 bladder cancer therapy J Urol 156 1996 1602 1605
76. T. Lebret, F. Gaudez, J.M. Herve Low-dose BCG instillations in the treatment of stage T1 grade 3 bladder tumours recurrence, progression and success Eur Urol 34 1998 67 72
77. M. Ayed, L. Ben Hassine, R. Ben Slama Results of BCG in the treatment of pTa and pT1 bladder tumors evaluation of a long protocol using 75 mg of Pasteur strain BCG Prog Urol 8 1998 206 210
78. J. Baniel, D. Grauss, D. Engelstein Intravesical bacillus Calmette-Guérin treatment for stage T1 grade 3 transitional cell carcinoma of the bladder Urology 52 1998 785 789
79. K. Gohji, M. Nomi, M. Okamto Conservative therapy for stage T1b, grade 3 transitional cell carcinoma of the bladder Urology 53 1999 308 313
80. P. Geavlete, D. Georgescu, I. Arabagiu Topical immunotherapy with BCG in the adjuvant treatment of superficial bladder tumors 15-year experience Chirurgia (Bucur) 95 2000 157 168 in Romanian
81. M. Brake, H. Loertzer, R. Horsch Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guérin J Urol 163 2000 1697 1701
82. M. Brake, H. Loertzer, R. Horsch Long-term results of intravesical bacillus Calmette-Guérin therapy for stage T1 superficial bladder cancer Urology 55 2000 673 678
83. J.J. Patard, S. Moudouni, F. Saint Tumor progression and survival in patients with T1G3 bladder tumors multicentric retrospective study comparing 94 patients treated during 17 years Urology 58 2001 551 556
84. E. Pieras Ayala, J. Palau, L. Rodriguez-Villamil Cystoscopic follow-up of initial G3T1 bladder tumors treated with BCG Arch Esp Urol 54 2001 211 217 in Spanish
85. J.N. Kulkarni, R. Gupta Recurrence and progression in stage T1G3 bladder tumour with intravesical bacille Calmette-Guérin (Danish 1331 strain) BJU Int 90 2002 554 557
86. T.R. Griffiths, M. Charlton, D.E. Neal Treatment of carcinoma in situ with intravesical bacillus Calmette-Guérin without maintenance J Urol 167 2002 2408 2412
87. J. Bogdanovic, G. Marusic, J. Djozic The management of T1G3 bladder cancer Urol Int 69 2002 263 265
88. M. Peyromaure, F. Guerin, D. Amsellem-Ouazana Intravesical bacillus Calmette-Guérin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder recurrence, progression and survival in a study of 57 patients J Urol 169 2003 2110 2112
89. C.W. Cheng, S.F. Chan, L.W. Chan 15-year experience on intravesical therapy of T1G3 urinary bladder cancer a conservative approach Jpn J Clin Oncol 34 2004 202 205
90. H.W. Herr, G. Dalbagni Defining bacillus Calmette-Guérin refractory superficial bladder tumors J Urol 169 2003 1706 1708
91. E.A. Klein, A. Rogatko, H.W. Herr Management of local bacillus Calmette-Guérin failures in superficial bladder cancer J Urol 147 1992 601 605
92. R.W. Glashan A randomized controlled study of intravesical alpha-2b-interferon in carcinoma in situ of the bladder J Urol 144 1990 658 661
93. M.F. Sarosdy, M.J. Manyak, A.I. Sagalowsky Oral bropirimine immunotherapy of bladder carcinoma in situ after prior intravesical bacille Calmette-Guérin Urology 51 1998 226 231
94. G. Dalbagni, P. Russo, J. Sheinfeld Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladder J Clin Oncol 20 2002 3193 3198
95. M.A. O'Donnell, J. Krohn, W.C. DeWolf Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guérin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guérin alone previously failed J Urol 166 2001 1300 1304
96. L.G. Luciani, E. Neulander, W.M. Murphy Risk of continued intravesical therapy and delayed cystectomy in BCG-refractory superficial bladder cancer an investigational approach Urology 58 2001 376 379
97. V. Pansadoro, F. De Paula Intravesical bacillus Calmette-Guérin in the treatment of superficial transitional cell carcinoma of the bladder J Urol 138 1987 299 301
98. D.E. Coplen, M.D. Marcus, J.A. Myers Long-term followup of patients treated with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guérin analysis of possible predictors of response free of tumor J Urol 144 1990 652 657
99. P.U. Malmstrom, H. Wijkstrom, C. Lundholm Swedish-Norwegian Bladder Cancer Study Group 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guérin in patients with superficial bladder carcinoma J Urol 161 1999 1124 1127
100. G. Steinberg, R. Bahnson, S. Brosman Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guérin refractory carcinoma in situ of the bladder J Urol 163 2000 761 767
101. A.S. Belldegrun, J.R. Franklin, M.A. O'Donnell Superficial bladder cancer the role of interferon-alpha J Urol 159 1998 1793 1801
102. J. Portillo, B. Martin, R. Hernandez Results at 43 months' follow-up of a double-blind, randomized, prospective clinical trial using intravesical interferon alpha-2b in the prophylaxis of stage pT1 transitional cell carcinoma of the bladder Urology 49 1997 187 190
103. S.P. Punnen, J.L. Chin, M.A. Jewett Management of bacillus Calmette-Guérin (BCG) refractory superficial bladder cancer results with intravesical BCG and interferon combination therapy Can J Urol 10 2003 1790 1795
104. J.S. Lam, M.C. Benson, M.A. O'Donnell Bacillus Calmette-Guérin plus interferon-alpha2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity Urol Oncol 21 2003 354 360
105. M.A. O'Donnell, K. Lilli, C. Leopold Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon alfa-2B for superficial bladder cancer J Urol 176 2004 888 892
106. A.P. Berger, H. Steiner, A. Stenzl Photodynamic therapy with intravesical instillation of 5-aminolevulinic acid for patients with recurrent superficial bladder cancer a single center study Urology 61 2003 338 341
107. J. Dunst, R. Sauer, K.M. Schrott Organ-sparing treatment of advanced bladder cancer a 10-year experience Int J Radiat Oncol Biol Phys 30 1994 261 266
108. C. Rodel, J. Dunst, G.G. Grabenbauer Radiotherapy is an effective treatment for high-risk T1-bladder cancer Strahlenther Onkol 177 2001 82 88